Dr. Ponni V. Perumalswami is an Assistant Professor of Medicine in the Division of Liver Diseases at the Mount Sinai School of Medicine. She earned her B.S. from the University of Michigan, graduating with honors. She completed her Internal Medicine residency at George Washington University. She went on to complete fellowship training in Gastroenterology at New York University and a Transplant Hepatology fellowship at the Mount Sinai Medical Center.
Dr. Perumalswami's areas of clinical interest include cirrhosis, acute/chronic liver diseases and liver transplantation. Her research program focuses on community outreach for hepatitis B and C screening and linking patients to care. She is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B and C.
Dr. Perumalswami is an UNOS-certified Liver Transplant physician and is board certified in Internal Medicine, and Gastroenterology. She is also board eligible in Transplant Hepatology. Currently she is a member of the American Association for the Study of Liver Diseases, European Association for the Study of the Liver and the American Gastroenterology Association.
Dr. Perumalswami is fluent in English and Tamil.
BS, University of Michigan
MD, Wayne State University
MCR, Icahn School of Medicine at Mount Sinai
Transplant Hepatology Fellowship, Icahn Icahn School of Medicine at Mount Sinai
Residency, Internal Medicine
George Washington University
NYU Medical Center
English, Tamil (India)
Dr. Harold and Golden Lamport Research Award
Icahn School of Medicine at Mount Sinai, New York, New York
Department of Medicine Outstanding Medical Educator
Icahn School of Medicine at Mount Sinai, New York, New York
HBV and HCV Screening of African Urban Populations in NYC with Link to Care by a Patient Navigator: A New Model for Viral Hepatitis Community Outreach
American College of Gastroenterology Presidential Poster
Las Vegas, Nevada
Advanced Transplant Hepatology Fellowship Award
Icahn School of Medicine at Mount Sinai, New York, New York
AASLD Advanced Hepatology Award
Liver Transplant Fellowship
National American College of Gastroenterology Fellows Conference Distinguished Award Recognition
Hepatitis Outreach Network (HONE)
Hepatitis Outreach Network (HONE) is an observational study that is targeted to screen adult, minority groups in New York City who are at high risk for chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) and link them to care with providers in the community. All participants are offered combined HBV and HCV screening at no cost along with the option to enroll in an observational study at a variety of health fairs in the city. This study is a collaboration between Mount Sinai Medical Center Division of Liver Diseases and community providers.
A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial
The purpose of this study is to evaluate the response the subject had after they have completed participation in a Merck-sponsored treatment study for hepatitis C. They may qualify to take part in this research study because they have previously participated in a Merck-sponsor...
A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3
The purpose of this study is to determine whether the study drugs are safe tolerable and effective at reducing the amount of HCV in the blood. This is an open-label study meaning the subject, their study doctor/study staff, and the study sponsor AbbVie will know which study drugs...
A Long Term Follow-up Registry Study for Subjects Who Achieve A Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
The purpose of this study is to evaluate the response the subject had after they have completed participation in a Gilead-sponsored treatment study for hepatitis C. They may qualify to take part in this research study because they have previously participated in a Gilead-sponsore...
A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
The purpose of this study is to continue to evaluate the subjects HCV infection after they have completed participation in a Gilead-sponsored treatment study for hepatitis C. Subjects may qualify to take part in this research study, because they have previously participated in a ...
Perumalswami PV, Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Motamed D, Khaitova V, Chang C, Grewal P, Liu L, Schiano TD, Woodward M, Dieterich DT, Branch AD. High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens. Journal of viral hepatitis 2016 Mar;.
Shankar H, Blanas D, Bichoupan K, Ndiaye D, Carmody E, Martel-Laferriere V, Culpepper-Morgan J, Dieterich DT, Branch AD, Bekele M, Nichols K, Perumalswami PV. A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Jun; 62 Suppl 4.
Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Gardenier D, Ng M, Motamed D, Khaitova V, Bach N, Chang C, Grewal P, Bansal M, Agarwal R, Liu L, Im G, Leong J, Kim-Schluger L, Odin J, Ahmad J, Friedman S, Dieterich D, Schiano T, Perumalswami P, Branch A. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. World journal of gastroenterology 2016 Mar; 22(9).
Del Bello D, Cha A, Sorbera M, Bichoupan K, Levine C, Doyle E, Harty A, Patel N, Ng M, Gardenier D, Odin J, Schiano TD, Fierer DS, Berkowitz L, Perumalswami PV, Dieterich DT, Branch AD. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Jun; 62(12).
Hartman J, Bichoupan K, Patel N, Chekuri S, Harty A, Dieterich D, Perumalswami P, Branch AD. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. World journal of gastroenterology 2015 Nov; 21(43).
Hearn B, Chasan R, Bichoupan K, Suprun M, Bagiella E, Dieterich DT, Perumalswami P, Branch AD, Huprikar S. Low adherence of HIV providers to practice guidelines for hepatocellular carcinoma screening in HIV/hepatitis B coinfection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Dec; 61(11).
Nadkarni GN, Patel A, Simoes PK, Yacoub R, Annapureddy N, Kamat S, Konstantinidis I, Perumalswami P, Branch A, Coca SG, Wyatt CM. Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis. Journal of viral hepatitis 2016 Jan; 23(1).
Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus. World journal of gastroenterology 2015 May; 21(20).
Martel-Laferrière V, Michel A, Schaefer S, Bindal S, Bichoupan K, Branch AD, Huprikar S, Schiano TD, Perumalswami PV. Clinical characteristics of human immunodeficiency virus patients being referred for liver transplant evaluation: a descriptive cohort study. Transplant infectious disease : an official journal of the Transplantation Society 2015 Aug; 17(4).
Branch-Elliman W, Perumalswami P, Factor SH, Sled SM, Flamm SL. Rates of recurrent variceal bleeding are low with modern esophageal banding strategies: a retrospective cohort study. Scandinavian journal of gastroenterology 2015; 50(9).
Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Perumalswami PV, Schiano TD, Odin JA, Liu L, Moskowitz AJ, Dieterich DT, Branch AD. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (Baltimore, Md.) 2014 Oct; 60(4).
Blanas DA, Nichols K, Bekele M, Shankar H, Bekele S, Jandorf L, Izzeldin S, Ndiaye D, Traore A, Bassam M, Perumalswami PV. Adapting the Andersen model to a francophone West African immigrant population: hepatitis B screening and linkage to care in New York City. Journal of community health 2015 Feb; 40(1).
Sefcik RK, Bichoupan K, Martel-Laferrière V, Odin JA, Liu LU, Perumalswami P, Bansal M, Dieterich DT, Ahmad J, Schiano TD, Branch AD. Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4. The Journal of infectious diseases 2014 Dec; 210(11).
Sriphanlop P, Jandorf L, Kairouz C, Thelemaque L, Shankar H, Perumalswami P. Factors related to hepatitis B screening among Africans in New York City. American journal of health behavior 2014 Sep; 38(5).
Asselah T, Perumalswami PV, Dieterich D. Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity. Liver international : official journal of the International Association for the Study of the Liver 2014 Nov; 34(10).
Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Commentary: real-world triple therapy experience treating hepatitis C virus - authors' reply. Alimentary pharmacology & therapeutics 2014 Mar; 39(5).
Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Alimentary pharmacology & therapeutics 2014 Jan; 39(2).
Han H, Perumalswami PV, Kleinman LC, Jandorf LH. Voices of multi-ethnic providers in NYC: health care for viral hepatitis to prevent hepatocellular carcinoma. Journal of cancer education : the official journal of the American Association for Cancer Education 2014 Jun; 29(2).
Law MJ, Deibler GE, Martenson RE, Krutzsch HC. Cleavage of rabbit myelin basic protein by plasmin: isolation and identification of the major products. Journal of neurochemistry 1985 Oct; 45(4).
Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich D, Branch A. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV medicine 2014 Feb; 15(2).
Perumalswami PV, DeWolfe Miller F, Orabee H, Regab A, Adams M, Kapelusznik L, Aljibawi F, Pagano W, Tong V, Dieterich DT. Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community. Liver international : official journal of the International Association for the Study of the Liver 2014 Feb; 34(2).
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. The New England journal of medicine 2013 May; 368(20).
Perumalswami PV, Factor SH, Kapelusznik L, Friedman SL, Pan CQ, Chang C, Di Clemente F, Dieterich DT. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. Journal of hepatology 2013 May; 58(5).
Perumalswami PV, Bini EJ. Epidemiology, natural history, and treatment of hepatitis B virus and hepatitis C virus coinfection. Minerva gastroenterologica e dietologica 2006 Jun; 52(2).
Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology (Baltimore, Md.) 2010 Mar; 51(3).
Scarpetta MA, Hawthorne CA, Brusilow WS. Characterization of semi-uncoupled hybrid Escherichia coli-Bacillus megaterium F1F0 proton-translocating ATPases. The Journal of biological chemistry 1991 Oct; 266(28).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Perumalswami has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.